Search

Your search keyword '"Clinical Haematology"' showing total 733 results

Search Constraints

Start Over You searched for: Author "Clinical Haematology" Remove constraint Author: "Clinical Haematology" Topic medicine Remove constraint Topic: medicine
733 results on '"Clinical Haematology"'

Search Results

1. Assessment of functional shunting in patients with sickle cell disease

2. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

3. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: 'What's Past Is Prologue' (Shakespeare)

4. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

5. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

6. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

7. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

8. WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes

9. Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study

10. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

11. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma

12. Oral health–related quality of life of patients with oral chronic graft-versus-host disease

13. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

14. Higher-order connections between stereotyped subsets

15. Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

16. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

17. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

18. Primary therapy and relative survival in classical Hodgkin lymphoma

19. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

20. Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

21. A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia

22. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

23. A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies

24. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

25. Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease

26. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

27. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

28. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

29. The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility

30. Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease; a randomized controlled trial

31. Cerebral oxygen metabolism in adults with sickle cell disease

32. Tailoring the amount of treatment information to cancer patients’ and survivors’ preferences: Effects on patient-reported outcomes

33. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

34. Cancer-related fatigue in hodgkin lymphoma

35. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands

36. Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016

37. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

38. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

39. Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients

40. Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016

41. Evans syndrome in adults:an observational multicenter study

42. A functional spleen contributes to afucosylated IgG in humans

43. Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

44. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

45. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

46. Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018

47. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia

48. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease

49. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease

50. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection

Catalog

Books, media, physical & digital resources